The Future Role Of Stem Cells As Antimicrobial Therapeutics | 38669
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
There are three main types of stem cells: (1) totipotent stem cells, (2) multipotent or adult stem cells that include mesenchymal
stem cells [MSCs], and (3) pluripotent stem cells that include embryonic stem cells [ESCs] and induced pluripotent stem cells
[iPSCs]. Recently, stem cell therapies have gained enormous potential as various types of stem cells have been shown to potentially
cure various intractable and chronic diseases. Two types of stem cells, MSCs and iPSCs, are receiving particular attention in the
treatment of various infectious complications. MSCs are heterogeneous progenitor cells that have the capacity of self-renewal and
multi-lineage differentiation. They can be obtained from several sources including: bone marrow (BM), peripheral blood, cord
blood, placenta, amniotic fluid, skin and adipose tissue. They have certain distinguishing features and their immunomodulatory
and immunosuppressive properties enable them to have several therapeutic applications. On the other hand, iPSCs can be derived
from a wide variety of cells and tissues, belonging to the three germ layers, and can avoid the obstacles and ethical issues that limit
the use of ESCs. Their reprogramming requires the presence of several elements. They exhibit specific stringency criteria and they
have certain identification properties. MSCs are essential constituents of the framework that supports organ integrity and tissue
Khalid Al-Anazi is a Consultant Hematologist and Head of Department of Adult Hematology and Hematopoietic Stem Cell Transplantation (HSCT) at King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Arabia. He graduated from the College of Medicine, King Saud University (KSU) in Riyadh, in the year 1986. After passing his Boards in Internal Medicine, he was trained in Clinical Hematology and HSCT at King’s College Hospital, University of London, U.K. He has 24 year experience in Adult Clinical Hematology and HSCT at Riyadh Armed Forces Hospital then King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, King Khalid University Hospital (KKUH) in Riyadh and KFSH in Dammam Saudi Arabia.